NASDAQ:BCEL Atreca (BCEL) Stock Forecast, Price & News $0.23 +0.00 (+0.04%) (As of 12:44 PM ET) Add Compare Share Share Today's Range$0.23▼$0.2550-Day Range$0.23▼$0.9852-Week Range$0.23▼$2.05Volume43,682 shsAverage Volume161,170 shsMarket Capitalization$9.04 millionP/E RatioN/ADividend YieldN/APrice Target$10.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Atreca MarketRank™ ForecastAnalyst RatingHold2.20 Rating ScoreUpside/Downside4,416.8% Upside$10.75 Price TargetShort InterestBearish9.38% of Float Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$9,085 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.64) to ($0.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.91 out of 5 stars 3.1 Analyst's Opinion Consensus RatingAtreca has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.75, Atreca has a forecasted upside of 4,416.8% from its current price of $0.24.Amount of Analyst CoverageAtreca has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.38% of the float of Atreca has been sold short.Short Interest Ratio / Days to CoverAtreca has a short interest ratio ("days to cover") of 13.7, which indicates bearish sentiment.Change versus previous monthShort interest in Atreca has recently decreased by 2.51%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAtreca does not currently pay a dividend.Dividend GrowthAtreca does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAtreca has received a 72.67% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Atreca is -0.85. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Atreca this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atreca insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,085.00 in company stock.Percentage Held by Insiders11.30% of the stock of Atreca is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 34.91% of the stock of Atreca is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Atreca are expected to grow in the coming year, from ($1.64) to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atreca is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atreca is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtreca has a P/B Ratio of 0.12. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Atreca (NASDAQ:BCEL) StockAtreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.Read More BCEL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCEL Stock News HeadlinesSeptember 30, 2023 | americanbankingnews.comAtreca, Inc. (NASDAQ:BCEL) Receives Average Recommendation of "Hold" from AnalystsSeptember 21, 2023 | finance.yahoo.comAtreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb CrossOctober 4, 2023 | Behind the Markets (Ad)BREAKING: The truth about war with ChinaForeign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.August 11, 2023 | msn.comHC Wainwright & Co. Downgrades Atreca Inc - (BCEL)August 11, 2023 | msn.comStifel Downgrades Atreca Inc - (BCEL)August 11, 2023 | finance.yahoo.comAtreca Reports Second Quarter 2023 Financial Results and Announces Corporate RestructuringAugust 2, 2023 | msn.comAtreca Inc - (BCEL) Price Target Increased by 11.89% to 10.20June 20, 2023 | msn.comAtreca Approaches A Major Go/No-Go DecisionOctober 4, 2023 | Behind the Markets (Ad)BREAKING: The truth about war with ChinaForeign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.June 6, 2023 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Atreca (BCEL)June 5, 2023 | msn.comHC Wainwright & Co. Reiterates Atreca Inc - (BCEL) Buy RecommendationJune 5, 2023 | finance.yahoo.comAtreca Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors during Oral Abstract Session at the ASCO 2023 Annual MeetingJune 5, 2023 | markets.businessinsider.comAtreca (BCEL) Gets a Buy from H.C. WainwrightJune 2, 2023 | fool.comAtreca (NASDAQ: BCEL)May 30, 2023 | markets.businessinsider.comStifel Nicolaus Sticks to Their Buy Rating for Atreca (BCEL)May 17, 2023 | ca.finance.yahoo.comAtreca, Inc. (BCEL) Interactive Stock Chart - Yahoo FinanceMay 14, 2023 | ca.finance.yahoo.comAtreca, Inc. (BCEL) Stock Historical Prices & Data - Yahoo FinanceMay 12, 2023 | msn.comHC Wainwright & Co. Reiterates Atreca, Inc. (BCEL) Buy RecommendationMay 11, 2023 | msn.comStifel Maintains Atreca, Inc. (BCEL) Buy RecommendationMay 11, 2023 | finanznachrichten.deAtreca, Inc.: Atreca Reports First Quarter 2023 Financial Results and Recent Corporate DevelopmentsMay 11, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Atreca (BCEL) and Oscar Health (OSCR)May 10, 2023 | finance.yahoo.comAtreca Reports First Quarter 2023 Financial Results and Recent Corporate DevelopmentsApril 26, 2023 | finance.yahoo.comAtreca Announces Oral Presentation of ATRC-101 Phase 1b Study Data at ASCO 2023 Annual MeetingApril 13, 2023 | finance.yahoo.comAtreca to Participate in the Canaccord Genuity Horizons in Oncology Virtual ConferenceApril 6, 2023 | finance.yahoo.comHere's Why Atreca, Inc. (BCEL) Is a Great 'Buy the Bottom' Stock NowApril 5, 2023 | finance.yahoo.comAre Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?March 23, 2023 | finance.yahoo.comAtreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023See More Headlines Receive BCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atreca and its competitors with MarketBeat's FREE daily newsletter. Email Address BCEL Company Calendar Last Earnings8/10/2023Today10/04/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BCEL CUSIPN/A CIK1532346 Webwww.atreca.com Phone(650) 595-2595FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.75 High Stock Price Forecast$25.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+4,416.8%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-97,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-120.73% Return on Assets-58.69% Debt Debt-to-Equity RatioN/A Current Ratio3.49 Quick Ratio3.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book0.12Miscellaneous Outstanding Shares39,300,000Free Float34,856,000Market Cap$9.35 million OptionableNot Optionable Beta1.24 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. John A. Orwin M.B.A. (Age 58)Pres, CEO, Director & Principal Financial Officer Comp: $927.03kDr. Tito A. Serafini Ph.D. (Age 60)Founder, Chief Strategy Officer & Director Comp: $665.5kDr. Stephen E. Gould Ph.D. (Age 58)Chief Scientific Officer Comp: $380.52kMr. Rick Ruiz (Age 59)Principal Accounting Officer Ms. Courtney J. Phillips J.D. (Age 48)Gen. Counsel & Corp. Sec. Dr. Philippe C. Bishop M.D. (Age 58)Chief Medical Officer More ExecutivesKey CompetitorsCadrenal TherapeuticsNASDAQ:CVKDVirpax PharmaceuticalsNASDAQ:VRPXGuardion Health SciencesNASDAQ:GHSILipella PharmaceuticalsNASDAQ:LIPOAraviveNASDAQ:ARAVView All CompetitorsInsiders & InstitutionsBill & Melinda Gates FoundationSold 74,764 shares on 8/15/2023Ownership: 2.380%BlackRock Inc.Sold 153,858 shares on 8/11/2023Ownership: 3.043%ExodusPoint Capital Management LPSold 43,058 shares on 8/11/2023Ownership: 1.192%Renaissance Technologies LLCBought 18,300 shares on 8/11/2023Ownership: 0.806%Acadian Asset Management LLCSold 21,747 shares on 8/7/2023Ownership: 0.113%View All Insider TransactionsView All Institutional Transactions BCEL Stock - Frequently Asked Questions Should I buy or sell Atreca stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atreca in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BCEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCEL, but not buy additional shares or sell existing shares. View BCEL analyst ratings or view top-rated stocks. What is Atreca's stock price forecast for 2023? 5 brokers have issued 1-year target prices for Atreca's stock. Their BCEL share price forecasts range from $4.00 to $25.00. On average, they predict the company's share price to reach $10.75 in the next year. This suggests a possible upside of 4,416.8% from the stock's current price. View analysts price targets for BCEL or view top-rated stocks among Wall Street analysts. How have BCEL shares performed in 2023? Atreca's stock was trading at $0.8006 at the beginning of the year. Since then, BCEL shares have decreased by 70.3% and is now trading at $0.2380. View the best growth stocks for 2023 here. When is Atreca's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our BCEL earnings forecast. How were Atreca's earnings last quarter? Atreca, Inc. (NASDAQ:BCEL) posted its earnings results on Thursday, August, 10th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.07. What is John Orwin's approval rating as Atreca's CEO? 6 employees have rated Atreca Chief Executive Officer John Orwin on Glassdoor.com. John Orwin has an approval rating of 100% among the company's employees. This puts John Orwin in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 90.0% of employees surveyed would recommend working at Atreca to a friend. What other stocks do shareholders of Atreca own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atreca investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Homology Medicines (FIXX), Akero Therapeutics (AKRO), Hookipa Pharma (HOOK), Lumentum (LITE), TCR2 Therapeutics (TCRR) and Precision BioSciences (DTIL). When did Atreca IPO? (BCEL) raised $126 million in an IPO on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI and Stifel served as the underwriters for the IPO and Canaccord Genuity and Brookline Capital Markets were co-managers. What is Atreca's stock symbol? Atreca trades on the NASDAQ under the ticker symbol "BCEL." How do I buy shares of Atreca? Shares of BCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Atreca's stock price today? One share of BCEL stock can currently be purchased for approximately $0.24. How much money does Atreca make? Atreca (NASDAQ:BCEL) has a market capitalization of $9.35 million. The company earns $-97,160,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis. How can I contact Atreca? Atreca's mailing address is 500 SAGINAW DRIVE FIRST FLOOR, REDWOOD CITY CA, 94063. The official website for the company is www.atreca.com. The company can be reached via phone at (650) 595-2595 or via email at ir@atreca.com. This page (NASDAQ:BCEL) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atreca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.